Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial
Christopher Farina, Michael H. Davidson, Prediman K. Shah, Charles W. Stark, Wenqi Lu, Cheerag Shirodaria, Timothy Wright, Charalambos Antoniades, Jan Nilsson, Nehal N. Mehta
Topics & Concepts
PsoriasisInflammationMedicinePlaceboInternal medicineRandomized controlled trialCardiologyInflammatory responseDouble blindPharmacologyImmunologyPathologyAlternative medicineCardiovascular Disease and AdiposityAtherosclerosis and Cardiovascular DiseasesAdipokines, Inflammation, and Metabolic Diseases